$CADL
Candel Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040984 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.020M $3.645M
YoY Change -14.59% -3.11%
% of Gross Profit
Research & Development $5.845M $5.934M
YoY Change 8.72% 18.16%
% of Gross Profit
Depreciation & Amortization $200.0K $236.0K
YoY Change -2.44% 26.2%
% of Gross Profit
Operating Expenses $8.861M $9.579M
YoY Change -0.57% 9.05%
Operating Profit -$8.861M -$9.579M
YoY Change -0.23% 9.44%
Interest Expense $669.0K $644.0K
YoY Change -480.11% -276.44%
% of Operating Profit
Other Income/Expense, Net $426.0K -$35.00K
YoY Change 120.73% -100.76%
Pretax Income -$8.440M -$9.614M
YoY Change -2.85% 131.72%
Income Tax
% Of Pretax Income
Net Earnings -$8.435M -$9.614M
YoY Change -2.91% 131.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29 -$0.33
Diluted Earnings Per Share -$0.29 -$0.33
COMMON SHARES
Basic Shares Outstanding 28.92M 28.92M
Diluted Shares Outstanding 28.92M 28.92M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.00M $51.89M
YoY Change -44.29% -40.2%
Cash & Equivalents $43.00M $51.90M
Short-Term Investments
Other Short-Term Assets $2.100M $1.468M
YoY Change 11.29% 169.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.10M $53.36M
YoY Change -42.96% -38.89%
LONG-TERM ASSETS
Property, Plant & Equipment $3.676M $3.981M
YoY Change -19.4% -12.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $425.0K
YoY Change 50.38% 59.77%
Total Long-Term Assets $4.960M $5.346M
YoY Change -16.46% -10.53%
TOTAL ASSETS
Total Short-Term Assets $45.10M $53.36M
Total Long-Term Assets $4.960M $5.346M
Total Assets $50.06M $58.71M
YoY Change -41.11% -37.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $250.0K $480.0K
YoY Change -74.23% -69.7%
Accrued Expenses $3.429M $3.495M
YoY Change -22.86% -7.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.100M $3.652M
YoY Change
Total Short-Term Liabilities $10.33M $8.163M
YoY Change 75.09% 38.87%
LONG-TERM LIABILITIES
Long-Term Debt $14.34M $16.70M
YoY Change -30.89% -19.04%
Other Long-Term Liabilities $1.600M $2.371M
YoY Change -74.33% -64.72%
Total Long-Term Liabilities $14.34M $16.70M
YoY Change -46.86% -38.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.33M $8.163M
Total Long-Term Liabilities $14.34M $16.70M
Total Liabilities $27.04M $27.94M
YoY Change -17.76% -15.93%
SHAREHOLDERS EQUITY
Retained Earnings -$125.9M -$117.5M
YoY Change 33.94% 37.75%
Common Stock $149.4M $148.7M
YoY Change 1.93% 1.97%
Preferred Stock
YoY Change
Treasury Stock (at cost) $448.0K $448.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $23.02M $30.77M
YoY Change
Total Liabilities & Shareholders Equity $50.06M $58.71M
YoY Change -41.11% -37.08%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$8.435M -$9.614M
YoY Change -2.91% 131.72%
Depreciation, Depletion And Amortization $200.0K $236.0K
YoY Change -2.44% 26.2%
Cash From Operating Activities -$8.810M -$7.195M
YoY Change -6.12% 1.38%
INVESTING ACTIVITIES
Capital Expenditures $100.0K $169.0K
YoY Change -146.51% -126.61%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$100.0K -$169.0K
YoY Change -53.49% -73.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -8.810M -7.195M
Cash From Investing Activities -100.0K -169.0K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -8.910M -7.364M
YoY Change -7.18% -4.49%
FREE CASH FLOW
Cash From Operating Activities -$8.810M -$7.195M
Capital Expenditures $100.0K $169.0K
Free Cash Flow -$8.910M -$7.364M
YoY Change -2.82% 13.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001841387
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40629
dei Entity Registrant Name
EntityRegistrantName
CANDEL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2214851
dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick St
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
916-5445
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CADL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28919810
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51894000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70058000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1468000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1887000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
53362000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
71945000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3981000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4424000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
940000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1056000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2023Q2 us-gaap Other Assets
OtherAssets
159000
CY2023Q2 us-gaap Assets
Assets
58708000
CY2022Q4 us-gaap Assets
Assets
77691000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
480000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
380000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3495000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4723000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
3652000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
464000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8163000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5615000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
120000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
144000
CY2023Q2 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
16703000
CY2022Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
20202000
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
700000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
648000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1237000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486000
CY2023Q2 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
1014000
CY2022Q4 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
1882000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19212000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17739000
CY2023Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
12000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
24000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
453000
CY2023Q2 us-gaap Liabilities
Liabilities
27937000
CY2022Q4 us-gaap Liabilities
Liabilities
29977000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
290000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
290000
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148427000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
146961000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117498000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99089000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58708000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77691000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5934000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5022000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11403000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10438000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3645000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3762000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7809000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7364000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9579000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8784000
us-gaap Operating Expenses
OperatingExpenses
19212000
us-gaap Operating Expenses
OperatingExpenses
17802000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9579000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8753000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1164000
us-gaap Investment Income Interest
InvestmentIncomeInterest
71000
CY2023Q2 us-gaap Interest Expense
InterestExpense
644000
CY2022Q2 us-gaap Interest Expense
InterestExpense
435000
us-gaap Interest Expense
InterestExpense
1253000
us-gaap Interest Expense
InterestExpense
611000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-144000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4969000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-868000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13256000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4604000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
803000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12716000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9614000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4149000
us-gaap Net Income Loss
NetIncomeLoss
-18409000
us-gaap Net Income Loss
NetIncomeLoss
-5023000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28810224
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28810224
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28750431
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28750431
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1544000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-78000
us-gaap Net Income Loss
NetIncomeLoss
-18409000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
39652000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
746000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-13000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9614000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64137000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
476000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
448000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1552000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-622000
us-gaap Net Income Loss
NetIncomeLoss
-5023000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60072000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
63762000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
470000
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
448000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
724000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-287000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4149000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60072000
us-gaap Profit Loss
ProfitLoss
-18409000
us-gaap Profit Loss
ProfitLoss
-5023000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
466000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
352000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-74000
us-gaap Share Based Compensation
ShareBasedCompensation
1466000
us-gaap Share Based Compensation
ShareBasedCompensation
930000
cadl Non Cash Lease Expense
NonCashLeaseExpense
116000
cadl Non Cash Lease Expense
NonCashLeaseExpense
101000
cadl Non Cash Interest Expense
NonCashInterestExpense
51000
cadl Non Cash Interest Expense
NonCashInterestExpense
44000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-868000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13256000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
154000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
115000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-419000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1760000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
159000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
87000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-161000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1162000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
276000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-24000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-63000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-225000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-225000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18014000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15150000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
307000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
806000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-806000
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
19910000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19938000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18164000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3982000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70324000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83066000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52160000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87048000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
168000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
133000
us-gaap Interest Paid Net
InterestPaidNet
1037000
us-gaap Interest Paid Net
InterestPaidNet
328000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2368000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
254000
cadl Common Stock Exchange For Option Exercise
CommonStockExchangeForOptionExercise
448000
cadl Number Of Product Candidates
NumberOfProductCandidates
2
us-gaap Net Income Loss
NetIncomeLoss
-18400000
us-gaap Net Income Loss
NetIncomeLoss
-5000000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117500000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation of the Company’s condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of stock-based option awards, valuations of warrants, and income taxes. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
cadl Cash And Cash Equivalent Maturity Period
CashAndCashEquivalentMaturityPeriod
P90D
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
300000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
300000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in-excess of the federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
cadl Expected Dividend Assumed
ExpectedDividendAssumed
0
cadl Percentage Income Taxes Benefits Upon Ultimate Settlement
PercentageIncomeTaxesBenefitsUponUltimateSettlement
0.50
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5576000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5553000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1595000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1129000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3981000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4424000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1952000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2647000
CY2023Q2 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1171000
CY2022Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1486000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
372000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
590000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3495000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4723000
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2022Q4 cadl Cash Proceeds Amount Equal To At Least From The Issuance And Sale Of Equity Securities
CashProceedsAmountEqualToAtLeastFromTheIssuanceAndSaleOfEquitySecurities
75000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8870000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10232000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
898000
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2023Q2 cadl Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
900000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
989000
CY2023Q2 cadl Debt Instrument Accretion Of Debt Discount
DebtInstrumentAccretionOfDebtDiscount
444000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20355000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
3652000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16703000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
35000
us-gaap Variable Lease Cost
VariableLeaseCost
85000
CY2023Q2 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
300000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
44000
us-gaap Variable Lease Cost
VariableLeaseCost
92000
CY2022Q2 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
300000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
289000
us-gaap Operating Lease Payments
OperatingLeasePayments
281000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2023Q2 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2022Q2 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
294000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
598000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
613000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
415000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1920000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
195000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1725000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16144365
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15077409
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1600756
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5645420
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1248603
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
470488
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.43
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6423535
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M25D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10000000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3252501
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M2D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5000000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3171034
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
2.49
cadl Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractual
P8Y9M29D
CY2023Q2 cadl Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedIntrinsicValue
5000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
800000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
733000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
438000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1466000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
929000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
6500000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
7300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M26D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M12D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
cadl Noncancelable Operating Lease Expiration Date
NoncancelableOperatingLeaseExpirationDate
2026
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9614000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4149000
us-gaap Net Income Loss
NetIncomeLoss
-18409000
us-gaap Net Income Loss
NetIncomeLoss
-5023000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28810224
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28810224
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28750431
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28750431
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14543609
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13158493

Files In Submission

Name View Source Status
0000950170-23-040984-index-headers.html Edgar Link pending
0000950170-23-040984-index.html Edgar Link pending
0000950170-23-040984.txt Edgar Link pending
0000950170-23-040984-xbrl.zip Edgar Link pending
cadl-20230630.htm Edgar Link pending
cadl-20230630.xsd Edgar Link pending
cadl-ex10_1.htm Edgar Link pending
cadl-ex10_2.htm Edgar Link pending
cadl-ex31_1.htm Edgar Link pending
cadl-ex31_2.htm Edgar Link pending
cadl-ex32_1.htm Edgar Link pending
cadl-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
cadl-20230630_def.xml Edgar Link unprocessable
cadl-20230630_lab.xml Edgar Link unprocessable
cadl-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cadl-20230630_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cadl-20230630_cal.xml Edgar Link unprocessable